Who is the CEO of Aptinyx Inc.?

Mr. Craig R. Jalbert CIRA is a business executive who currently serves as the CEO of Aptinyx Inc..

What is the Revenue Growth of Aptinyx Inc.?

Revenue growth data for Aptinyx Inc. is currently unavailable.

What is Aptinyx Inc. operating Margin?

Aptinyx Inc. operating margin is 0.00% which shows how much profit APTX earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does Aptinyx Inc. operate?

Aptinyx Inc. falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is Aptinyx Inc. revenue growth?

Revenue growth data for Aptinyx Inc. is currently unavailable.

Aptinyx Inc.

APTX•NASDAQ

HealthcareBiotechnology

$0.10

$0.003(3.17%)

Aptinyx Inc. (APTX) Stock Overview

Explore Aptinyx Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for APTXStats details for APTX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for APTXAnalyst Recommendations details for APTX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

CEO

Mr. Craig R. Jalbert CIRA

Employees

Headquarters

909 Davis Street, Evanston, IL

Founded

2018